-
Clinical isolates of ST131 blaOXA-244-positive Escherichia coli, Italy, December 2022 to July 2023
-
View Affiliations Hide AffiliationsVittoria Mattioni Marchettivittoria.mattionimarchetti unipv.it
-
View Citation Hide Citation
Citation style for this article: . Clinical isolates of ST131 blaOXA-244-positive Escherichia coli, Italy, December 2022 to July 2023. Euro Surveill. 2024;29(8):pii=2400073. https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400073 Received: 02 Feb 2024; Accepted: 22 Feb 2024
Abstract
The dissemination of carbapenemase-producing Escherichia coli, although still at low level, should be continuously monitored. OXA-244 is emerging in Europe, mainly in E. coli. In Italy, this carbapenemase was reported from an environmental river sample in 2019. We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.
Full text loading...